Copy Link Print Information

IFN-alpha/beta R2 Protein, Human (HEK293, His)

1 Cited Publications
Customer Review

Based on 1 publication(s) in Google Scholar

IFN-alpha/beta R2, one of the subunit of IFN-α/β receptor, is a type I IFN receptor. IFN-alpha/beta R2 forms the heterodimeric receptor with IFNAR1, and binds to type I IFNs. IFN-alpha/beta R2 also interacts with JAK1 and leads to tyrosine phosphorylation of the IFNARs and STAT proteins. Upon activation by these IFNs, IFNAR1 and IFN-alpha/beta R2 undergo a conformational change to promote a cascade of downstream signaling events, including the phosphorylation of Tyk2 and JAK1, STAT1 and STAT2. IFN-alpha/beta R2 Protein, Human (HEK293, His) is a recombinant human IFN-alpha/beta R2 (I27-K243) with C-terminal 6*His tag, which is produced in HEK293 cells.

For research use only. We do not sell to patients.
  • Species: Human
  • Source: HEK293
  • Storage:
    Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
  • Experimental Validation Results for IFN-alpha/beta R2 Protein, Human (HEK293, His)
  • Experimental Validation Results for IFN-alpha/beta R2 Protein, Human (HEK293, His)
  • IFN-alpha/beta R2 Protein, Human (HEK293, His) Product Image
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Service
Data Download

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Technical Parameters
  • Product Properties
  • Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Biological Activity

Description

IFN-alpha/beta R2, one of the subunit of IFN-α/β receptor, is a type I IFN receptor. IFN-alpha/beta R2 forms the heterodimeric receptor with IFNAR1, and binds to type I IFNs[1]. IFN-alpha/beta R2 also interacts with JAK1 and leads to tyrosine phosphorylation of the IFNARs and STAT proteins[2]. Upon activation by these IFNs, IFNAR1 and IFN-alpha/beta R2 undergo a conformational change to promote a cascade of downstream signaling events, including the phosphorylation of Tyk2 and JAK1, STAT1 and STAT2[3]. IFN-alpha/beta R2 Protein, Human (HEK293, His) is a recombinant human IFN-alpha/beta R2 (I27-K243) with C-terminal 6*His tag, which is produced in HEK293 cells.

Background

IFN-alpha/beta R2, one of the subunit of IFN-α/β receptor, is a type I IFN receptor. IFN-alpha/beta R2 is expressed on peripheral blood B cells and monocytes, and mediates differentiation and activation of these cells[4].
IFN-alpha/beta R2 forms the heterodimeric receptor (IFN-α/β receptor) together with IFNAR1. IFNs such as IFN-α/-β can induce association of the IFNAR1 and IFN-alpha/beta R2, which makes JAK1 and TYK2 form a functional signaling unit[1]. Upon activation by these IFNs, IFNAR1 and IFN-alpha/beta R2 undergo a conformational change to promote a cascade of downstream signaling events. The signaling events includes the phosphorylation of Tyk2 and JAK1, the signal transducers and activators of transcription STAT1 and STAT2, and the formation of the IFN-stimulated gene factor 3 (ISGF3) complex which consists of phosphorylated STAT1 and STAT2 and IRF9[3]. IFNAR2 is critical for anti-viral immunity[5].
Human IFN-alpha/beta R2 consists of extracellular domain (I27-K243), helical domain (I244-L264), and cytoplasmic domain (K265-R515). The sequence of amino acids in IFN-alpha/beta R2 differs in different species. Human IFN-alpha/beta R2 shares <50% aa sequence identity with mouse.
IFN-alpha/beta R2 mediates IFN-induced tyrosine phosphorylation of the IFNARs and STAT proteins, and activates the JAK-STAT signaling cascade[1]

In Vitro

IFN-alpha/beta R2 (human, 30 μg/mL, 4 h) down-regulates the production of IL-17 and IFN-γ in PBMCs[6].
IFN-alpha/beta R2 (human, 100 ng/mL, 40 h) reduces the cell proliferation rate in PBMCs[6].

Verified Bioactivity

1.Immobilized Human IFNA2 at 10 μg/mL (100 μL/well) can bind IFNAR2. The ED50 for this effect is 568.9 ng/mL.
2.Measured by its ability to inhibit rh IFNβ mediated protection of WISH Human amnion cells infected with vesicular stomatitis virus (VSV) to viral lysis.The EC50 for this effect is typically 1-4 μg/mL.

MCE Validation Data

  • Purity - SDS-PAGE

    Purity - SDS-PAGE

    ≥ 95%, as determined by reducing SDS-PAGE.

  • Bioactivity - ELISA

    Bioactivity - ELISA

    Immobilized Human IFNA2 at 10 μg/mL (100 μL/well) can bind IFNAR2 , The ED50 for this effect is 568.9 ng/mL.

Technical Parameters

  • Species Human
  • Source HEK293
  • Tag C-His
  • Accession

    P48551-1 (I27-K243)

  • Gene ID
    3455  [NCBI]
  • Molecular Construction
    • N-term
    • IFNAR2 (I27-K243)
      Accession # P48551-1
    • His
    • C-term
  • Protein Length

    Extracellular Domain

  • Synonyms

    IFNAR2; IFN-R-2; Prev. IFNABR; Interferon-Alpha/Beta Receptor Beta Chain; Interferon Alpha/Beta Receptor 2; Human Interferon Alpha/Beta Receptor; Type I Interferon Receptor 2; IFN-Alpha Binding Protein; Interferon (Alpha, Beta And Omega) Receptor 2; Inter

  • AA Sequence

    ISYDSPDYTDESCTFKISLRNFRSILSWELKNHSIVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLFSCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKKHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAESAK

  • Molecular Weight

    Approximately 34-55 kDa, based on SDS-PAGE under reducing conditions, due to the glycosylation.

  • Glycosylation

    Yes

  • Purity

    ≥ 95%, as determined by reducing SDS-PAGE.

Product Properties

Appearance

Lyophilized powder

Formulation

1.Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.
2.Lyophilized from a 0.22 μm filtered solution of 50 mM Tris-HCl, 300 mM NaCl, pH 7.4.
Please refer to the lot-specific COA for specific buffer information.
Note: For SPR assay, please replace the buffer. Primary amine components (e.g., Tris, imidazole) can affect protein-coupled chips.

Endotoxin Level

<1 EU/μg, determined by LAL method.

Reconstitution

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Storage & Stability

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Shipping

Room temperature in continental US; may vary elsewhere.

References

[1]. Zanin N, et al. Interferon Receptor Trafficking and Signaling: Journey to the Cross Roads. Front Immunol. 2021 Jan 20;11:615603. [Content Brief]

[2]. Shemesh M, et al. IFNAR1 and IFNAR2 play distinct roles in initiating type I interferon-induced JAK-STAT signaling and activating STATs. Sci Signal. 2021 Nov 23;14(710):eabe4627. [Content Brief]

[3]. Jun Zou, et al. Chapter 7 - Antiviral Immunity: Origin and Evolution in Vertebrates. The Evolution of the Immune System. 2016,Pages 173-204.

[4]. Pogue SL, et al. The receptor for type I IFNs is highly expressed on peripheral blood B cells and monocytes and mediates a distinct profile of differentiation and activation of these cells. J Interferon Cytokine Res. 2004 Feb;24(2):131-9. [Content Brief]

[5]. Duncan CJ, et al. Human IFNAR2 deficiency: Lessons for antiviral immunity. Sci Transl Med. 2015 Sep 30;7(307):307ra154. [Content Brief]

[6]. Hurtado-Guerrero I, et al. Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-β Mediation. J Clin Med. 2020 Mar 31;9(4):959. [Content Brief]

View More

Calculators

Reconstitution Calculator

Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration

Volume (to add to vial) Volume (to add to vial)
=
Mass (in vial) Mass (in vial)
÷
Desired Reconstitution Concentration Desired Reconstitution Concentration
Dilution Calculator

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

Concentration (start) Concentration (start)
×
Volume (start) Volume (start)
=
Concentration (final) Concentration (final)
×
Volume (final) Volume (final)
The Specific Activity Calculator Equation
  • Specific Activity (Unit/mg)
  • Biological Activity (ED50)

Specific Activity (Unit/mg) = 106 ÷ Biological Activity (ED50)

Specific Activity (Unit/mg) Specific Activity (Unit/mg)
Unit/mg
= 106 ÷
Biological Activity (ED50) Biological Activity (ED50)
106 ÷
ng/mL
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00

Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated CTLL-2 mouse cytotoxic T cells. The ED50 this effect is 0.8023 μg/ml, corresponding to a specific activity is 1246.42 units/mg.

Assay Types
  • 1/16

    MedChemExpress Validation
     ≥ 95%, as determined by reducing SDS-PAGE.

  • 1/16

    MedChemExpress Validation
     Immobilized Human IFNA2 at 10 μg/mL (100 μL/well) can bind IFNAR2 , The ED50 for this effect is 568.9 ng/mL.

  • IFN-alpha/beta R2 Protein, Human (HEK293, His) Product Image
    1/16
  • Experimental Validation Results for IFN-alpha/beta R2 Protein, Human (HEK293, His)
  • Experimental Validation Results for IFN-alpha/beta R2 Protein, Human (HEK293, His)
  • IFN-alpha/beta R2 Protein, Human (HEK293, His) Product Image